Compare MPB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | PCRX |
|---|---|---|
| Founded | 1868 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 1.1B |
| IPO Year | 1996 | 2010 |
| Metric | MPB | PCRX |
|---|---|---|
| Price | $36.83 | $24.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $30.25 |
| AVG Volume (30 Days) | 70.5K | ★ 432.4K |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 1.22 | 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $30.95 | $6.78 |
| Revenue Next Year | $9.45 | $8.54 |
| P/E Ratio | ★ $30.16 | $128.84 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $26.56 | $18.80 |
| 52 Week High | $39.15 | $27.66 |
| Indicator | MPB | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 45.26 |
| Support Level | $35.87 | $24.61 |
| Resistance Level | $37.37 | $27.05 |
| Average True Range (ATR) | 0.75 | 0.73 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 47.06 | 30.67 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.